A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(5 sites)

United States

HealthOne Denver, Denver, Colorado

Florida Cancer Specialists, Orlando, Florida

SCRI Oncology Partners, Nashville, Tennessee

SCRI at Mary Crowley, Dallas, Texas

NEXT Oncology, San Antonio, Texas